OrbiMed’s Post

Only put off until tomorrow what you are willing to die having left undone. Capricor Therapeutics to Present at Piper Sandler and Oppenheimer Investor Conferences in December 2024 Quiver AI Summary: Capricor Therapeutics will be presenting at two upcoming investor conferences, showcasing their exosome-based therapeutics and clinical developments. The first conference is the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, followed by the Oppenheimer Movers in Rare Disease Summit on December 12, 2024. This presents a valuable opportunity for investors to gain insights into Capricor's innovative approach in the healthcare industry. Investing in HSA accounts can provide numerous benefits, including tax advantages and potential long-term growth. By staying informed about companies like Capricor Therapeutics, investors can explore promising opportunities within the healthcare sector. This announcement highlights the company's commitment to advancing exosome-based therapeutics, which could have significant implications for the future of medical treatments. As an investor, it's crucial to stay ahead of the curve and take advantage of such opportunities. Don't miss out on the chance to learn more about Capricor Therapeutics and their cutting-edge developments. Stay proactive, research, and consider investing in companies that are revolutionizing the healthcare industry. #hsa #investing #healthcare #health #family #wellness 💼📈🏥💪🌱 Remember, your Health Savings Account can be an excellent tool for building wealth while prioritizing your well-being. Act now to avoid the Fear of Missing Out (FOMO) and seize the potential growth opportunities in this ever-evolving sector.

Spartan Capital Securities, LLC is excited to welcome Chromocell Therapeutics Corporation (NYSE: CHRO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain.   This one-day event brings together public company executives, institutional investors, and capital market leaders. With over 30 presenting companies, it promises an unparalleled networking experience.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

Discover how we identify participants for our Decoy20 clinical trials at Indaptus Therapeutics. VP of Clinical Operations, Jeffery Nieves explains our thorough process, from collaborating with healthcare professionals across the US to conducting rigorous screenings. Learn about our dedicated approach to selecting the right patients for our studies. #ClinicalTrials #CancerResearch #PatientSafety #biotech #BladderCancer

We're honored to welcome Chromocell Therapeutics Corporation (NYSE: $CHRO) to participate in the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital who made this event possible: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. Spartan Capital Securities, LLC is a full-service, integrated financial services firm trusted by high-net-worth individuals and institutions for sound investment guidance. We focus on understanding our clients' objectives and executing strategies to meet their financial goals. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

How will the Inflation Reduction Act (IRA) impact oncology drugs? From setting a maximum fair price for a drug to scheduling some oncology drugs for Medicare price negotiation, the IRA presents unique challenges and considerations for biopharmaceutical research companies moving forward. Learn more in our full infographic: https://lnkd.in/di8jEHqn #IRA Medicare #Biopharma #Oncology

# Only put off until tomorrow what you are willing to die having left undone ## Discover the Future of Healthcare Investment: Autolus Therapeutics Shines at ASH 2024! Investors, seize this opportunity to stay ahead in the race to financial success! Autolus Therapeutics presents groundbreaking data at the prestigious American Society of Hematology \(ASH\) Annual Meeting, shedding light on their revolutionary drug obe-cel for adult relapsed/refractory B-ALL patients. With exceptional clinical outcomes and remarkable cost efficiency, Autolus Therapeutics is revolutionizing the treatment landscape. Harness the power of healthcare investment by taking action now! Don't let the Fear of Missing Out hold you back. Embrace the potential for growth and prosperity while making a significant impact on the world of healthcare. Invest in Autolus Therapeutics today and secure your position in the future of medicine. #hsa #investing #healthcare #health #family #wellness 💪✨🏥💰 Investment advisory disclaimer: The above recommendation is not personalized financial advice. Please consult with a qualified financial advisor before making any investment decisions.

Very interesting article for those working in #marketaccess and #commercialization of #radioligandtherapies! Check it out:

Spartan Capital Securities, LLC is excited to welcome Chromocell Therapeutics Corporation (NYSE: CHRO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Chromocell is a pioneer in the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. The Company’s programs targeting the treatment of chronic neuropathic and acute and chronic eye pain are based on its patented core molecules. Chromocell Therapeutics Corp.'s leadership team includes Frank Knuettel II, Eric Lang, Simon P. Chandler, Richard Malamut, and Anke Hoppe. Conference attendees will be uniquely able to engage directly with Chromocell Therapeutics Corp. executives, gaining valuable insights into the company’s development and commercializing new therapeutics to alleviate pain.   This one-day event brings together public company executives, institutional investors, and capital market leaders. With over 30 presenting companies, it promises an unparalleled networking experience.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #ChromocellTherapeutics #CHRO

This podcast recording from the 2023 PODD: Partnership Opportunities in Drug Delivery Conference focuses on transnasal delivery of therapeutics to the brain and features representatives from Harvard Medical School, Eli Lilly and Company, and Seelos Therapeutics, Inc. Listen to the podcast here: https://lnkd.in/e9vBXqC6 #PODD2023 #PODD2024 #DrugDelivery #Formulations #Transnasal #therapeutics #DrugDevelopment